Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in CHF (TTM)60.50bn
- Net income in CHF8.28bn
- Incorporated1966
- Employees103.25k
- LocationRoche Holding AGGrenzacherstrasse 124BASEL 4002SwitzerlandCHE
- Phone+41 616881111
- Websitehttps://www.roche.com/
| Holder | Shares | % Held |
|---|---|---|
| Canada Pension Plan Investment Boardas of 31 Mar 2024 | 1.92m | 1.80% |
| UBS Asset Management Switzerland AGas of 30 Jun 2025 | 1.41m | 1.32% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 1.24m | 1.16% |
| APG Asset Management NVas of 31 Dec 2023 | 1.19m | 1.12% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 719.63k | 0.68% |
| Z�rcher Kantonalbank (Investment Management)as of 30 May 2025 | 572.87k | 0.54% |
| Geode Capital Management LLCas of 04 Jul 2025 | 335.70k | 0.32% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 317.70k | 0.30% |
| Vontobel Asset Management AGas of 31 May 2025 | 253.73k | 0.24% |
| BlackRock Asset Management Deutschland AGas of 03 Jul 2025 | 218.32k | 0.21% |
